SCHEMBL3909794

SCHEMBL3909794

COc1ccc2oc(=O)cc(OCCCN)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ HPGD P15428 4/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ DYRK1A Q13627 1/20 0.54
▸ NPC1 O15118 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ CASP3 P42574 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ SENP8 Q96LD8 1/20 0.50
▸ SENP7 Q9BQF6 1/20 0.50
▸ SENP6 Q9GZR1 1/20 0.50
▸ KCNA3 P22001 1/20 0.50
▸ CYP19A1 P11511 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ MTNR1A P48039 1/20 0.46
▸ MTNR1B P49286 1/20 0.46
▸ PRKDC P78527 1/20 0.46
▸ KMT2A Q03164 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3913777 0.90 KDM4E (0.46) KDM4EALDH1A1HPGDHSD17B10DYRK1A
SCHEMBL3915220 0.90 CYP19A1 (0.60) KDM4EALDH1A1HPGDHSD17B10KCNA3
SCHEMBL3918826 0.84 KCNA3 (0.49) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL15842463 0.81 KDM4E (0.71) KDM4EALDH1A1HPGDHSD17B10DYRK1A
SCHEMBL3918101 0.81 KCNA3 (0.49) KCNA3CYP19A1NQO1
SCHEMBL3911254 0.81 KCNA3 (0.49) ALDH1A1DYRK1AKCNA3PRKDCNQO1
SCHEMBL3920158 0.81 PIM1 (0.50) KDM4EHSD17B10KCNA3CYP19A1
Trifluoroacetic Acid SCHEMBL3914730 0.81 CYP19A1 (0.52) KDM4EALDH1A1HPGDHSD17B10KCNA3
SCHEMBL3912517 0.79 KCNA3 (0.72) KCNA3CYP19A1NQO1
SCHEMBL13842107 0.79 KCNA3 (0.47) ALDH1A1KCNA3CYP19A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1667988-A1 COUMARINS AS INOS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-06-14 — — EP claimed
WO-2005026143-A1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 — — WO claimed
US-20050054681-A1 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-03-10 — — US claimed
US-7538233-B2 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-05-26 — — US disclosed
US-7538233-B2 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-05-26 — — US disclosed
EP-1667988-A1 COUMARINS AS INOS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-06-14 — — EP disclosed
WO-2005026143-A1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 — — WO disclosed
US-20050054681-A1 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054681-A1 Coumarins as iNOS inhibitors NOS2, NOS1, NOS3 KDM4E 3645/4885ALDH1A1 169/4885HPGD 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback